Eli Lilly Invests $700 Million in New Boston RNA and DNA Research Facility

Expanding Research Capabilities

Eli Lilly and Company is investing approximately $700 million in a new state-of-the-art research and development center in the Boston Seaport. The Lilly Institute for Genetic Medicine will focus on RNA and DNA-based research, boosting Lilly's capabilities in these rapidly growing fields.

Key Features of the New Facility

* 334,000 square feet of laboratory and office space * Located in the Seaport neighborhood of Boston, a hub for biotechnology and innovation * Dedicated to the research and development of RNA and DNA-based therapies * Expected to be completed in 2023

The investment in the new facility reflects Lilly's commitment to advancing RNA and DNA-based research. These technologies have shown great promise in treating a wide range of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

Benefits of the New Facility

* Expands Lilly's research capabilities in RNA and DNA-based therapies * Fosters collaboration with leading scientists and institutions in the Boston area * Creates new jobs and supports the local economy * Contributes to the advancement of medical research and innovation

The Lilly Institute for Genetic Medicine is expected to be completed in 2023. It will be a significant addition to Lilly's global research network and is expected to play a key role in the development of new treatments for patients.